These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16001476)

  • 21. South Korea continues up ladder of biotech leaders.
    He-suk C
    Biotechnol J; 2006 Sep; 1(9):900-1. PubMed ID: 16986101
    [No Abstract]   [Full Text] [Related]  

  • 22. Transparent communication strategy on GMOs: will it change public opinion?
    Sinemus K; Egelhofer M
    Biotechnol J; 2007 Sep; 2(9):1141-6. PubMed ID: 17703492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off the rails.
    Nat Biotechnol; 2008 Mar; 26(3):247. PubMed ID: 18327213
    [No Abstract]   [Full Text] [Related]  

  • 24. Biotech regulation in India: problems and promises.
    Reddy KI
    Biotechnol J; 2009 Mar; 4(3):306-9. PubMed ID: 19296437
    [No Abstract]   [Full Text] [Related]  

  • 25. Fuelling the 9 billion.
    Martindale W; Trewavas A
    Nat Biotechnol; 2008 Oct; 26(10):1068-70. PubMed ID: 18846065
    [No Abstract]   [Full Text] [Related]  

  • 26. Off the rails or on the mark?
    Chataway J; Tait J; Wield D
    Nat Biotechnol; 2008 May; 26(5):500-1. PubMed ID: 18464777
    [No Abstract]   [Full Text] [Related]  

  • 27. Off the rails or on the mark?
    Heinemann JA
    Nat Biotechnol; 2008 May; 26(5):499-500. PubMed ID: 18464776
    [No Abstract]   [Full Text] [Related]  

  • 28. The difficulty of structuring and focusing the co-existence debate in Europe.
    Custers R
    Biotechnol J; 2007 Sep; 2(9):1086-7. PubMed ID: 17703493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perfect time or perfect crime?
    Danchin A
    EMBO Rep; 2010 Feb; 11(2):74. PubMed ID: 20118987
    [No Abstract]   [Full Text] [Related]  

  • 30. Biotech, the environment and the three Ps.
    Gannon F
    EMBO Rep; 2005 Jun; 6(6):489. PubMed ID: 15940277
    [No Abstract]   [Full Text] [Related]  

  • 31. Animal cloning and the FDA--the risk assessment paradigm under public scrutiny.
    Rudenko L; Matheson JC; Sundlof SF
    Nat Biotechnol; 2007 Jan; 25(1):39-43. PubMed ID: 17211392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 33. Trivial pursuits.
    Nat Biotechnol; 2002 Apr; 20(4):319. PubMed ID: 11923818
    [No Abstract]   [Full Text] [Related]  

  • 34. A green light for engineered algae: redirecting metabolism to fuel a biotechnology revolution.
    Rosenberg JN; Oyler GA; Wilkinson L; Betenbaugh MJ
    Curr Opin Biotechnol; 2008 Oct; 19(5):430-6. PubMed ID: 18725295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 20-year African biotech plan.
    Singh JA; Daar AS
    Nat Biotechnol; 2008 Mar; 26(3):272-4. PubMed ID: 18327231
    [No Abstract]   [Full Text] [Related]  

  • 36. Exploring emerging nanobiotechnology drugs and medical devices.
    Paradise J; Diliberto GM; Tisdale AW; Kokkoli E
    Food Drug Law J; 2008; 63(2):407-20. PubMed ID: 18561467
    [No Abstract]   [Full Text] [Related]  

  • 37. [Nanobiotechnology in pharmacology and medicine].
    Sikyta B
    Ceska Slov Farm; 2001 Nov; 50(6):263-6. PubMed ID: 11797193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inherited wealth.
    Wyke A
    Economist; 1988 Apr; 307():3-18. PubMed ID: 17256228
    [No Abstract]   [Full Text] [Related]  

  • 39. The biotechnology revolution and its regulatory evolution.
    Hoffman DE
    Drake Law Rev; 1988-1989; 38(3):471-550. PubMed ID: 16086466
    [No Abstract]   [Full Text] [Related]  

  • 40. The promise and perils of synthetic biology.
    Tucker JB; Zilinskas RA
    New Atlantis; 2006; 12():25-45. PubMed ID: 16832953
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.